A bit more about the Panama Canal malarkey with various references to 'CK Hutchison'. It's from 'BBC Verify' - just as bad / ridiculous as their 'disinformation' correspondent - but I am guessing that its publication is to serve some purpose. |
 Mcmather - sentiment towards HK/China is poor in the west. No doubt HK/China is sceptical of the value of western operations represented in HK companies. So CKHH gets a double negative view. CKHH as a conglomerate trades at a hefty discount - if you add the market value of its listed subs you get the mcap of the parent. One might think the logical answer is a break up and realisation of the value of the assets…….
There is little synergy within the CK group of companies for Hutchmed to exploit and it seems to have been on its own for a while with CKHH selling down to under 40%.
Hutchmed seems to be inhabiting a nether world where it has grown into a commercial organisation, but its larger competitors are interested in smaller bolt on acquisitions. Eventually the mid sized companies will need to huddle together to avoid being preyed upon or accept they will be only a bit part player in the background.
The Sovlep manufacturing issue is just the latest in a steady flow of mis-steps. I think it is time for Victor to make a trade in HCM. |
Double yer money from here...
"Feb. 11, 2025, 09:25 AM
BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target" |
AZ reported 2024 sales of Orpathys of $46m. This is flat for the year, and up 2% at CER.
The expansion to 1L should give this a boost, but the key is getting the SACHI and SAVANNAH combo with Tagrisso approved during 2025. There is no news on the FDA application - it did have breakthrough designation allowing a rolling submission - surely the submission is nearly complete after which I anticipate a PDUFA date of a further 6-9 months.
The China combination is not expected to be before the US approval (per the company timeline for product launches), but both Tagrisso and Savolitinib are individually approved, so we might expect something closer to the 7 months for the EMC combo than a 12-16m typical approval. |
A constant drip drip of selling since the end of October. |
HUTCHMED Announces Delay in Circular Dispatch for Major Transaction
TipRanks UK Auto-Generated Newsdesk
Jan 28, 2025, 10:02 AM
Story Highlights
HUTCHMED plans to divest a 45% stake in Shanghai Hutchison Pharmaceuticals.
The dispatch of transaction details is postponed until February 28, 2025.
HUTCHMED (China) Limited ( HK:0013 -1.42% ▼ ) just unveiled an announcement.
HUTCHMED (China) Limited announced a major transaction involving the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited, valued at US$608 million. The dispatch of the circular detailing this transaction has been delayed until February 28, 2025, due to additional time needed by GP Health Service Capital to finalize details. This delay is attributed to the Chinese New Year holidays, and stakeholders are advised to exercise caution regarding the deal’s completion, as it is contingent on the satisfaction of certain conditions.
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company dedicated to the discovery and global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought its first three cancer medicines to market in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: -6.81%
Average Trading Volume: 55,198
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.88B
TipRanks’ Stock Analysis page. |
RNS Number : 9427U
Hutchmed (China) Limited
28 January 2025
Overseas Regulatory Announcement -
Disposal Transaction
HUTCHMED (China) Limited ("HUTCHMED") notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The text relates to the dispatch timing of the extraordinary general meeting circular that relates to the transaction described in the announcement dated January 2, 2025, entitled "HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture".
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial‑stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing cancer drug candidates from in‑house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
+852 2121 8200 / ir@hutch-med.com |
It does seem Tacked can get approvals for Fruzaqla wherever it wants….but what is key is the prices being negotiated for access to state funded healthcare systems. Spain was the first in the EU in December, the UK decision is due in early March. Only once these negotiations are complete will there be significant sales.
Takeda reports Oct-Dec sales on Thursday 30 Jan. The 2024 sales by quarter in USD were 50/80/75m. Q3 may be lowered by fewer hospital appts over the summer. Tak started sales in JPN and EU during H2, I am expecting a result in the 80-100m range with a bias towards 85-90m as most likely. |
A bit of news from Monday:
“Takeda Canada Reports Market Authorization For FRUZAQLA In Canada - Quick Facts
January 20, 2025 — 08:11 am EST”
More here; |
Last hour:
"Innovent Biologics ( HK:1801 -10.31% ▼ ) has issued an announcement.
Innovent Biologics has reported unusual price and trading volume movements in its shares but confirmed no changes in its business operations or any undisclosed information". |
Can but laugh - from yesterday's UK close to the price earlier, circa £230m wiped off the market cap. |
Followed by a near 10% fall in HK on no further news…. |
Press Release
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
- Indication expands to include treatment-naïve patients -
- The 2021 conditional approval in previously treated patients converted to full approval -
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alteration. The NMPA has also converted the prior conditional approval of ORPATHYS® in the previously treated patient population to full approval. The new label indication for ORPATHYS® will now include both treatment-naïve and previously treated patients in China. |
Trinity Delta today: HUTCHMED has secured divestment proceeds to advance its innovative pipeline, including its newly disclosed proprietary next-generation antibody-targeted therapy conjugate (ATTC) platform, through monetising a 45% equity interest in a non-core JV (joint venture). This divestment sharpens the focus onto HUTCHMED’s core business and will enable investment into the early-stage ATTC platform. Cash proceeds of c $608m provide additional financial flexibility as HUTCHMED executes on its goal of sustainable profitability from FY25 onwards. Funds will be directed towards progressing the Oncology/Immunology R&D pipeline – including ATTC assets – and supporting commercialisation of new and existing products in China. Ahead of deal close in Q125 our HUTCHMED valuation remains $5.94bn/£4.95bn/HK$46.31bn, equivalent to $34.07/ADS and 568p/HK$53.14 per share. |
Some good news to kick-start 2025 off: HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy |
Disappointingly they say it is all destined for pipeline development. |
And today a deal to dispose of SHPL has been announced for $608m.
Call on Tuesday, EGM required due to size of the transaction.
What will they do with this extra cash…..no fund raise was expected to deliver the pipeline….so it will likely mean M&A, or return to Shareholders (BB or divi?)
Shorts likely to run for the hills would be my guess and an opening jump in the share price on 2 Jan. |
Any ideas what the appointment of Cavendish means?
This is from the cavendish website
Cavendish is a trusted advisor to both public and private companies across various industry sectors. We deliver expert services in equity capital markets, M&A, debt advisory, and private growth capital. Our membership of Oaklins, the world’s foremost mid-market mergers and acquisitions advisor, gives us access to 60 offices in 40 countries, ensuring unparalleled global coverage.
We specialise in providing our clients with access to equity, debt, and alternative financing, as well as offering cross-border M&A advice. Our extensive experience, drive, and proactive approach make Cavendish the ideal partner for ambitious companies. |
Good news again. Will it have any effect on the share price?
Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. |
HCM deserves more than the only +4p of the day, even after also recovering from a poor opening.
Folks will surely catch on as the days go by, if they have the insight.
f |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
